IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

COATES et al.

Examiner: F. Krass

Serial No.: 07/835,964

Group Art Unit: 1614

Filed: February 20, 1992

For:

1,3-OXATHIOLANE NUCLEOSIDE ANALOGUES

AMENDMENT UNDER 37 C.E.R. \$1.312(a)

Assistant Commissioner for Patents Washington, DC 20231

SIR

Further to the amendment of March 10, 2000, entry of the following amendments is respectfully requested.

IN THE CLAIMS

Please amend claims 25, 31, 32, 64-67, and 81-82 as follows:

25. A method for treating a human suffering from HIV infection comprising administering to said human [a pharmaceutical composition comprising]:

a compound which is (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt thereof [, another agent having antiviral activity,] and a pharmaceutically acceptable carrier, [and] wherein the amount of the (+)-enantiomer of said compound or of said pharmaceutically acceptable salt present in said composition is no more than 5% w/w, relative to the combined weight of the (-) and (+)-enantiomers thereof and

another agent having antivital activity.

- 31. A method according to claim 25, wherein [said composition contains an] the amount of the (+)-enantiomer is [of] no more than 2% w/w.
- 32. A method according to claim 31, wherein [said composition contains an] the amount of the (+)-enantiomer is [of] no more than 1% w/w

Aderica to the state of

IAFG-14